Suppr超能文献

天然产物在管理和治疗新型冠状病毒感染中的潜在治疗方式:基于临床前和临床的证据。

Natural Products, a Potential Therapeutic Modality in Management and Treatment of nCoV-19 Infection: Preclinical and Clinical Based Evidence.

机构信息

Department of Pharmacology, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi-110062, India.

Department of Pharmaceutics, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi-110062, India.

出版信息

Curr Pharm Des. 2021;27(9):1153-1169. doi: 10.2174/1381612827999210111190855.

Abstract

A recent outbreak of novel coronavirus (nCoV-19) has put an enormous burden on global public health. Millions of people were affected by this pandemic, and as of now, no effective antiviral drug has been found for the management of this situation. Cytokine storm, acute respiratory distress, hypoxia and multi-organ failure are hallmark clinical conditions of this disease. Trials for several investigational and repurposed drugs are being conducted, but none of them were found to be safe and effective. However, for the critically ill patient, plasma therapy, dexamethasone, and remdesivir are included in the treatment protocol. For a long time, various natural drugs have been used as antiviral agents in Indian and Chinese traditional medicines, which can be explored as a potential therapeutic option in such situation. It is, therefore, speculated that the proper screening and standardization of these medicines can be a breakthrough in the management and treatment of nCoV-19 infection. As natural products possess antioxidant, anti-inflammatory, anti-apoptotic, immunomodulatory properties and also specifically act on various viral enzymatic machinery and affect their replication process, thus they may be useful as alternatives in relieving symptoms and treatment of nCoV-19 infection. However, only on the basis of their traditional value, discrimination and off-label use of these natural drugs must be prevented, and robust preclinical and clinical data along with appropriate guidelines are needed for them to enter into clinical practice.

摘要

最近爆发的新型冠状病毒(nCoV-19)给全球公共卫生带来了巨大负担。数百万人受到这种大流行的影响,到目前为止,还没有找到有效的抗病毒药物来治疗这种情况。细胞因子风暴、急性呼吸窘迫、缺氧和多器官衰竭是这种疾病的典型临床特征。正在对几种研究性和重新定位的药物进行临床试验,但都没有发现它们是安全有效的。然而,对于重症患者,血浆疗法、地塞米松和瑞德西韦被纳入治疗方案。长期以来,各种天然药物一直被用作印度和中国传统医学中的抗病毒药物,在这种情况下可以作为一种潜在的治疗选择进行探索。因此,有人推测,对这些药物进行适当的筛选和标准化可能是管理和治疗 nCoV-19 感染的突破点。由于天然产物具有抗氧化、抗炎、抗凋亡、免疫调节特性,并且专门作用于各种病毒酶机制并影响其复制过程,因此它们可能有助于缓解症状和治疗 nCoV-19 感染。然而,必须防止仅仅基于其传统价值而对这些天然药物进行歧视和非标签使用,并且需要有强有力的临床前和临床数据以及适当的指南,才能将这些药物纳入临床实践。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验